The effects of low dose acetylsalicylic acid on treatment and recurrence of acute central serous chorioretinopathy Akut santral seröz korioretinopatide düşük doz asetilsalisilik asitin tedavi ve nüks üzerine etkisi

ELİAÇIK M., Karaman S., Anil Aslan C., ŞENTÜRK F., ARAS C., KAYA F.

Retina-Vitreus, vol.24, no.4, pp.301-304, 2016 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2016
  • Journal Name: Retina-Vitreus
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.301-304
  • Keywords: Acetylsalicylic acid, Central serous chorioretinopathy, Optical coherence tomography
  • Istanbul Medipol University Affiliated: Yes


Purpose: To investigate the effect of added low dose acetylsalicylic acid for the treatment and recurrence of central serous chorioretinopathy (CSCR). Materials and Methods: The clinical data for 60 eyes of 60 patients with CSCR admitted to our clinic, between November 2010 and November 2013 were studied retrospectively. The demographic characteristics, best-corrected visual acuity and optical coherence tomography central retinal thickness of all patients were recorded. Patients were divided into two groups according to their treatments; oral acetozolamide and topical nepafenac 0.1% (Group A) and oral acetozolamide, topical nepafenac 0.1% plus low dose acetylsalicylic acid (Group B). The two treatment groups were compared with age, sex, visual acuity, macular thickness and recurrence. Results: At the first visit mean best-corrected visual acuity was 0.15±0.11 LogMAR and 0.18±0.13 LogMAR and in Group A and Group B, respectively (p=0.43). The mean central retinal thickness at baseline was 406±61 mm and407±56 mm in Group A and Group B, respectively (p=0.879). No statistically significant difference was found in visual acuity and macular thickness between the two groups at 1 week, 1., 3. or 6 months of medication. At the follow-up 12 patients (37%) in group A (n=32) and 4 patients (14%) in group B (n=28) had a second attack. Conclusion: Although our results could not confirm a benefit of add the low dose acetylsalicylic acid to oral acetozolamide and topical nepefenac 0.1% therapy on visual acuity and macular thickness, but patients receiving acetylsalicylic acid had a lower recurrence rate in acute CSCR.